Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Bought by Quest Partners LLC

Quest Partners LLC grew its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 271.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,654 shares of the company’s stock after purchasing an additional 4,131 shares during the quarter. Quest Partners LLC’s holdings in Spyre Therapeutics were worth $166,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC acquired a new position in shares of Spyre Therapeutics during the 2nd quarter valued at about $43,238,000. Assenagon Asset Management S.A. acquired a new position in shares of Spyre Therapeutics during the 3rd quarter valued at about $33,609,000. Driehaus Capital Management LLC acquired a new position in shares of Spyre Therapeutics during the 2nd quarter valued at about $16,153,000. Farallon Capital Management LLC acquired a new position in shares of Spyre Therapeutics during the 2nd quarter valued at about $15,658,000. Finally, Logos Global Management LP acquired a new position in shares of Spyre Therapeutics during the 2nd quarter valued at about $13,518,000. Institutional investors and hedge funds own 80.39% of the company’s stock.

Spyre Therapeutics Trading Down 0.3 %

SYRE stock opened at $27.75 on Thursday. The company has a market capitalization of $1.43 billion, a P/E ratio of -3.72 and a beta of 2.90. Spyre Therapeutics, Inc. has a twelve month low of $10.42 and a twelve month high of $47.97. The business has a 50 day simple moving average of $31.18 and a 200-day simple moving average of $29.98.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Guggenheim boosted their price target on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Wedbush restated an “outperform” rating and issued a $45.00 price objective on shares of Spyre Therapeutics in a report on Friday, November 8th. Finally, Robert W. Baird boosted their price objective on shares of Spyre Therapeutics from $50.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $48.57.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).